BRPI1013777A2 - compostos agonistas do receptor 5-ht4 para tratamento de distúrbios cognitivos. - Google Patents

compostos agonistas do receptor 5-ht4 para tratamento de distúrbios cognitivos.

Info

Publication number
BRPI1013777A2
BRPI1013777A2 BRPI1013777A BRPI1013777A BRPI1013777A2 BR PI1013777 A2 BRPI1013777 A2 BR PI1013777A2 BR PI1013777 A BRPI1013777 A BR PI1013777A BR PI1013777 A BRPI1013777 A BR PI1013777A BR PI1013777 A2 BRPI1013777 A2 BR PI1013777A2
Authority
BR
Brazil
Prior art keywords
treatment
receptor agonist
cognitive disorders
agonist compounds
compounds
Prior art date
Application number
BRPI1013777A
Other languages
English (en)
Inventor
David Beattie
Fei Shen
Jacqueline A M Smith
Ray Chang
Robert Murray Mc
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of BRPI1013777A2 publication Critical patent/BRPI1013777A2/pt
Publication of BRPI1013777A8 publication Critical patent/BRPI1013777A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1013777A 2009-04-13 2010-04-12 Compostos agonistas do receptor 5-ht4 para tratamento de distúrbios cognitivos. BRPI1013777A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16874109P 2009-04-13 2009-04-13
US29255910P 2010-01-06 2010-01-06
PCT/US2010/030760 WO2010120695A2 (en) 2009-04-13 2010-04-12 5-ht4 receptor agonist compounds for treatment of cognitive disorders

Publications (2)

Publication Number Publication Date
BRPI1013777A2 true BRPI1013777A2 (pt) 2016-04-05
BRPI1013777A8 BRPI1013777A8 (pt) 2017-09-19

Family

ID=42237213

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013777A BRPI1013777A8 (pt) 2009-04-13 2010-04-12 Compostos agonistas do receptor 5-ht4 para tratamento de distúrbios cognitivos.

Country Status (24)

Country Link
US (2) US8404711B2 (pt)
EP (1) EP2419104B1 (pt)
JP (1) JP2012523437A (pt)
KR (1) KR20120017421A (pt)
CN (2) CN102395371A (pt)
AU (1) AU2010236734B2 (pt)
BR (1) BRPI1013777A8 (pt)
CA (1) CA2758321A1 (pt)
CY (1) CY1119800T1 (pt)
DK (1) DK2419104T3 (pt)
ES (1) ES2654930T3 (pt)
HR (1) HRP20180018T1 (pt)
HU (1) HUE038141T2 (pt)
IL (1) IL215660A0 (pt)
LT (1) LT2419104T (pt)
MX (1) MX2011010782A (pt)
NO (1) NO2419104T3 (pt)
PL (1) PL2419104T3 (pt)
PT (1) PT2419104T (pt)
RU (1) RU2569056C2 (pt)
SI (1) SI2419104T1 (pt)
SM (1) SMT201800036T1 (pt)
WO (1) WO2010120695A2 (pt)
ZA (1) ZA201107490B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
HUE026815T2 (en) 2008-11-19 2016-07-28 Forum Pharmaceuticals Inc Treatment of Cognitive Disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
AU2010247835A1 (en) * 2009-05-11 2011-12-08 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
TWI519532B (zh) 2010-05-17 2016-02-01 艾維沃製藥公司 (R)-7-氯-N-(啶-3-基)苯並[b]噻吩-2-羧醯胺鹽酸鹽單水合物之結晶形體
RU2017136693A (ru) 2012-05-08 2019-02-08 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции
JP6009080B2 (ja) 2012-08-16 2016-10-19 ユニバーシティ−インダストリー コオペレーション グループ オブ キョン ヒ ユニバーシティUniversity−Industry Cooperation Group Of Kyung Hee University 老化及び認知症の予防及び/または治療活性を有する乳酸菌
US10874701B2 (en) 2012-08-16 2020-12-29 University-Industry Cooperation Group Of Kyung Hee University Lactic acid bacteria capable of preventing and/or treating senescence and dementia
RS61704B1 (sr) 2017-05-24 2021-05-31 H Lundbeck As Kombinacija antagonista 5-ht6 receptora i inhibitora acetilholinesteraze za upotrebu u lečenju alchajmerove bolesti kod subpopulacije pacijenata koji nose apoe4 alele
CN116585316A (zh) 2017-06-01 2023-08-15 卫材R&D管理有限公司 包含pde9抑制剂的药物组合物
JP7282028B2 (ja) 2017-06-02 2023-05-26 富士フイルム富山化学株式会社 脳萎縮予防または治療剤
CA3069989C (en) 2017-07-31 2025-05-06 Alfasigma S.P.A. METHODS FOR TREATING GASTROPARESIA SYMPTOMS USING VELUSETRAG

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60124730T2 (de) * 2000-03-03 2007-10-04 Eisai R&D Management Co., Ltd. Neue methoden unter verwendung von cholinesteraseinhibitoren
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7598265B2 (en) * 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
TWI377206B (en) 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists

Also Published As

Publication number Publication date
US20140057939A1 (en) 2014-02-27
JP2012523437A (ja) 2012-10-04
CY1119800T1 (el) 2018-06-27
HRP20180018T1 (hr) 2018-02-09
US8404711B2 (en) 2013-03-26
KR20120017421A (ko) 2012-02-28
AU2010236734B2 (en) 2015-06-11
LT2419104T (lt) 2018-02-12
IL215660A0 (en) 2012-01-31
WO2010120695A3 (en) 2010-12-02
EP2419104B1 (en) 2017-11-08
NO2419104T3 (pt) 2018-04-07
PT2419104T (pt) 2018-01-31
DK2419104T3 (en) 2018-02-05
AU2010236734A1 (en) 2011-11-03
RU2569056C2 (ru) 2015-11-20
WO2010120695A2 (en) 2010-10-21
BRPI1013777A8 (pt) 2017-09-19
EP2419104A2 (en) 2012-02-22
PL2419104T3 (pl) 2018-04-30
SMT201800036T1 (it) 2018-03-08
ZA201107490B (en) 2012-06-27
US20100261752A1 (en) 2010-10-14
AU2010236734A8 (en) 2012-02-16
RU2011146032A (ru) 2013-05-20
ES2654930T3 (es) 2018-02-15
CN105832735A (zh) 2016-08-10
HUE038141T2 (hu) 2018-10-29
SI2419104T1 (en) 2018-03-30
CA2758321A1 (en) 2010-10-21
MX2011010782A (es) 2012-01-20
CN102395371A (zh) 2012-03-28

Similar Documents

Publication Publication Date Title
BRPI0912362A2 (pt) antagonista do receptor nmda para o tratamento de transtornos neuropsiquiátricos
ZA201107490B (en) 5-ht4 receptor agonist compounds for treatment of cognitive disorders
BRPI0918527A2 (pt) compostos para o tratamento de disturbios do cns
UY33094A (es) Procedimiento para la preparacion de dronedarona
BR112012013260A2 (pt) dispositivo usado para o tratamento de rinite através de iluminação bioestimulativa
BRPI1015250A2 (pt) métodos de estabilização e de hidrogenação para olefinas micróbio-derivadas
IL225758A0 (en) Preparations containing combinations of serotonin agonists and their uses
BRPI1015274A2 (pt) instalação para o tratamento de superfície de peças
BR112013014943A2 (pt) compostos úteis para o tratamento de aids
DK2440230T3 (da) Behandlingsregimener til behandling af neurologisk sygdom
BRPI0813516A2 (pt) Tratamento de distúrbios proliferativos de células b
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
BRPI1007404A2 (pt) método para síntese de (1s,2r)-milnaciprano
BRPI0924916A2 (pt) Equipamento para atenção integral de neonatos críticos.
BR112012004836A2 (pt) pirazinilpiridinas úteis para o tratamento de doenças proliferativas
HUE033690T2 (hu) Terápiás szer hangulatzavarokra
BR112013012072A2 (pt) derivados, composições de benzodiazepina e métodos para o tratamento de danos cognitivos
PT2623499E (pt) Derivado de 1,2,4-triazolona para tratamento de distúrbios de humor
BRPI1008008A2 (pt) usos de antagonistas do receptor de nk
EP2540721A4 (en) GHRELIN RECEPTOR AGONIST FOR DYSKRASY TREATMENT
BRPI0812034A2 (pt) Combinações de neramexano para o tratamento de distúrbios neurodegenerativos
EP2552423A4 (en) STABILIZED FORMULATIONS OF CNS COMPOUNDS
PT2467140T (pt) Lapatinib para tratamento do cancro
BRPI0915761A2 (pt) composto de heterociclila para tratamento de doença cardiovascular
BR112012002267A2 (pt) compostos para o tratamento de inflamação.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: THERAVANCE BIOPHARMA RANDD IP, LLC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]